logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Matthew T. Campbell

The University of Texas MD Anderson Cancer Center
H指数:33
被引数:8,351

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study

恩沃利单抗联合帕博利珠单抗治疗尿路上皮癌患者肺炎的发生率及危险因素：回顾性研究

Oncologist
IF4.2
2026-09-170
OAAI
Luis Angel Diaz Tejada; Fabiana Alexandra Príncipe Osorio; Abdelrahman M Attia; Ivan Alexander Flores Hernandez; Emilio Jacques Villarreal; Omar Alhalabi; Matthew T Campbell; Cindy Y Jiang; Zachariah Thomas; Girish S Shroff; Mehmet Altan; Jianjun Gao; Ajay Sheshadri; null
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

在恩沃利单抗之后的尿路上皮癌患者中，萨cituzumab govitecan的疗效：UNITE研究的分析

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
IF2.3
2025-12-010
OAAI
Jindal, Tanya; Jiang, Cindy Y.; Alhalabi, Omar; Davidsohn, Matthew; Freeman, Dory; Epstein, Ilana Y.; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Nizam, Amanda; Nguyen, Charles B.; Oh, Eugene; Tsung, Irene; Glover, Michael J.; Khaki, Ali Raza; Taylor, Amy K.; Jaime-Casas, Salvador; Jang, Albert; Lemke, Emily; Pywell, Cameron; Evans, Sean T.; Shin, Denny; Bilen, Mehmet A.; Basu, Arnab; Kilari, Deepak; Tripathi, Abhishek; Brown, Jason; Emamekhoo, Hamid; Davis, Nancy B.; Shah, Sumit; Gupta, Shilpa; Grivas, Petros; Bellmunt, Joaquim; Alva, Ajjai; Campbell, Matthew T.; Koshkin, Vadim S.
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

FGFR3突变型晚期尿路上皮癌中，erdafitinib在enfortumab vedotin治疗前或治疗后的疗效：UNITE协作研究的分析

ONCOLOGIST
IF4.2
2025-11-010
PRE
Jiang, Cindy Y.; Hwang, Hyunsoo; Epstein, Ilana Y.; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Taylor, Amy K.; Nizam, Amanda; Jindal, Tanya; Glover, Michael J.; Khaki, Ali Raza; Barata, Pedro C.; Nguyen, Charles B.; Oh, Eugene; Davis, Nancy B.; Mabey, Hannah; Hoimes, Christopher J.; Evans, Sean T.; Abuqayas, Bashar; Lemke, Emily; Tsung, Irene; Qiao, Wei; Kilari, Deepak; Zakharia, Yousef; Bilen, Mehmet A.; Milowsky, Matthew, I; Shah, Sumit A.; Gupta, Shilpa; Emamekhoo, Hamid; Bellmunt, Joaquim; Alva, Ajjai S.; Grivas, Petros; Msaouel, Pavlos; Koshkin, Vadim S.; Campbell, Matthew T.; Alhalabi, Omar
Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma

II期研究： dostarlimab 联合 niraparib 治疗III期-IV期复发性或难治性阴茎鳞状细胞癌

Future Oncology
IF2.6
2025-10-300
PRE
Firas Hatoum; Gabriel Roman Souza; Jeff Johnson; Justin Miller; Adnan Fazili; Curtis Alvin Pettaway; Matthew T. Campbell; Robin Neubauer; Andrew Johns; Sarah Raymond Mizelle; Youngchul Kim; Juskaran Chadha; Jingsong Zhang; Ghazal Jameel; Erika Oschmann; Jasreman Dhillon; Anay Moscu; Ryan Janeway; Walt Harris; Xin Lu; Philippe E. Spiess; Jad Chahoud
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机II期试验，比较仑伐替尼联合依维莫司与卡博替尼在PD-1免疫检查点抑制剂进展后的转移性透明细胞肾细胞癌患者中的疗效（LenCabo）。

Annals of Oncology
IF65.4
2025-10-180
PRE
A.W. Hahn; J. Chahoud; W.P. Skelton; Y. Yuan; A.J. Zurita; C. Kovitz; O. Alhalabi; M.T. Campbell; E. Jonasch; J. Lin; M. Desai; M.J.M.N. Santos; H. Hwang; P.G. Corn; P. Msaouel; N.M. Tannir
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局：UNITE研究的分析

CANCER MEDICINE
IF3.1
2025-10-020
OAAI
Nizam, Amanda; Nguyen, Charles B.; Li, Jinju; Zabor, Emily C.; Msaouel, Pavlos; Jiang, Cindy Y.; Alhalabi, Omar; Oh, Eugene; Davidsohn, Matthew P.; Epstein, Ilana B.; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Jindal, Tanya; Taylor, Amy K.; Glover, Michael J.; Khaki, Ali Raza; Lemke, Emily; Mabey, Hannah; Abuqayas, Bashar; Jang, Albert; Brown, Jason R.; Evans, Sean T.; Pywell, Cameron; Basu, Arnab; Bilen, Mehmet A.; Barata, Pedro C.; Zakharia, Yousef; Milowsky, Matthew I.; Kilari, Deepak; Hoimes, Christopher J.; Shah, Sumit A.; Emamekhoo, Hamid; Davis, Nancy B.; Gupta, Shilpa; Grivas, Petros; Bellmunt, Joaquim; Campbell, Matthew T.; Alva, Ajjai S.; Koshkin, Vadim S.
20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)

II期临床试验：评估ivonescimab在既往接受过免疫检查点阻断治疗的晚期透明细胞肾细胞癌患者中的疗效（IVORY试验，NCT06940518）。

ONCOLOGIST
IF4.2
2025-10-010
OAAI
Dizman, Nazli; Slack-Tidwell, Rebecca S.; Sheth, Rahul A.; Alhalabi, Omar; Campbell, Matthew T.; Corn, Paul G.; Goswami, Sangeeta; Johns, Andrew; Jonasch, Eric; Lin, John K.; Shah, Amishi Y.; Wang, Jianbo; Zurita-Saavedra, Amado J.; Gao, Jianjun; Tannir, Nizar; Hahn, Andrew W.; Msaouel, Pavlos
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

恩福妥单抗（Enfortumab Vedotin）在具有不同组织学亚型的晚期尿路上皮癌患者中的疗效：UNITE研究的分析

European Urology
IF25.2
2025-09-140
PRE
Tanya Jindal; Cindy Y. Jiang; Omar Alhalabi; Charles B. Nguyen; Eugene Oh; Irene Tsung; Dimitra Rafailia Bakaloudi; Rafee Talukder; Matthew Davidsohn; Dory Freeman; Ilana Y. Epstein; Chien-Kuang Cornelia Ding; Amanda Nizam; Michael J. Glover; Ali Raza Khaki; Amy K. Taylor; Emily Lemke; Albert Jang; Sean T. Evans; Denny Shin; Cameron Pywell; Arnab Basu; Mehmet A. Bilen; Yousef Zakharia; Pedro Barata; Matthew I. Milowsky; Jason Brown; Deepak Kilari; Hamid Emamekhoo; Christopher J. Hoimes; Sumit Shah; Nancy B. Davis; Shilpa Gupta; Petros Grivas; Joaquim Bellmunt; Ajjai Alva; Matthew T. Campbell; Vadim S. Koshkin
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

寡转移性透明细胞肾细胞癌的转移灶定向放射治疗（无系统性治疗）：一项单臂、单中心、II期试验的主要疗效分析

lancet oncology
IF0
2025-09-040
PRE
Chad Tang; Alexander D Sherry; Aaron Seo; Kieko Hara; Haesun Choi; Suyu Liu; Xiaowen Sun; Anya Montoya; Ethan B Ludmir; Amishi Y Shah; Eric Jonasch; Amado J Zurita; Craig Kovitz; Omar Alhalabi; Sangeeta Goswami; Andrew W Hahn; Matthew T Campbell; Arianna Hernandez; Kevin T Nead; Peter Van Loo; Shiqin Su; Christopher J Battey; Matthew L LaBella; Sarah Ratzel; Ashley Acevedo; Giannicola Genovese; Kanishka Sircar; Jose A Karam; Nizar M Tannir; Pavlos Msaouel
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?

接受恩诺单抗 vedotin 和帕博利珠单抗治疗的晚期尿路上皮癌：治愈之路？

ONCOLOGIST
IF4.2
2025-09-011
OAAI
Jang, Albert; Tripathi, Nikita; Lanka, Sree M.; Kumar, Hamsa L. S.; Jain, Prateek; Calaway, Adam; Shoag, Jonathan E.; Vince, Randy; Mendiratta, Prateek; Rao, Santosh; Garcia, Jorge A.; Brown, Jason R.; Koshkin, Vadim S.; Campbell, Matthew T.; Singh, Parminder; Barata, Pedro C.
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

开发生物标志物和风险分层方法：国际肾癌研讨会北美2024年思辨研讨会的共识声明

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
IF2.3
2025-09-010
PRE
Shapiro, Daniel D.; Abel, Edwin Jason; Albiges, Laurence; Battle, Dena; Berg, Stephanie A.; Campbell, Matthew T.; Cella, David; Coleman, Katie; Garmezy, Benjamin; Geynisman, Daniel M.; Hall, Tasha; Henske, Elizabeth P.; Jonasch, Eric; Karam, Jose A.; La Rosa, Salvatore; Leibovich, Bradley C.; Maranchie, Jodi K.; Master, Viraj A.; Maughan, Benjamin L.; Mcgregor, Bradley A.; Msaouel, Pavlos; Pal, Sumanta K.; Perez, Jose; Plimack, Elizabeth R.; Psutka, Sarah P.; Riaz, Irbaz B.; Rini, Brian I.; Shuch, Brian; Simon, Marie Celeste; Singer, Eric A.; Smith, Andrew; Staehler, Michael; Tang, Chad; Tannir, Nizar M.; Vaishampayan, Ulka; Voss, Martin H.; Zakharia, Yousef; Zhang, Qing; Zhang, Tian; Carlo, Maria I.
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

I期b/II期研究：评估batiraxcept单药及联合cabozantinib（无论是否联合nivolumab）治疗晚期透明细胞肾细胞癌的疗效。

ONCOLOGIST
IF4.2
2025-06-010
PRE
Beckermann, Kathryn E.; Shah, Neil J.; Campbell, Matthew T.; Haas, Naomi B.; Nelson, Ariel; Ornstein, Moshe C.; Mao, Shifeng; Keshava-Prasad, Holavanahalli S.; Hammers, Hans; Gao, Xin; Gourdin, Theodore; George, Saby; Hoimes, Christopher J.; Hussain, Arif; Jonasch, Eric; Rini, Brian, I; Voss, Martin H.
Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

avelumab联合达沙替尼与舒尼替尼作为晚期肾细胞癌患者的一线治疗：JAVELIN Renal 101 III期试验的最终分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-013
PRE
Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; Eertwegh, A. J. M. van den; Negrier, S.; Gurney, H.; Albiges, L.; Berger, R.; Haanen, J. B. A. G.; Juarez, V. Oyervides; Rini, B. I.; Larkin, J.; Nole, F.; Schmidinger, M.; Atkins, M. B.; Tomita, Y.; Ellers-Lenz, B.; Hoffman, J.; Sandner, R.; Wang, J.; di Pietro, A.; Motzer, R. J.
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

与恩夫妥单抗韦汀疗效相关的基因组生物标志物：对UNITE研究数据的分析

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-12-011
OAAI
Jindal, Tanya; Jiang, Cindy; Alhalabi, Omar; Nizam, Amanda; Nguyen, Charles; Talukder, Rafee; Bakaloudi, Dimitra; Davidsohn, Matthew; Freeman, Dory; Glover, Michael; Khaki, Ali Raza; Evans, Sean; Lemke, Emily; Bose, Rohit; Sim, Woogwang; Pywell, Cameron; Basu, Arnab; Kilari, Deepak; Barata, Pedro C.; Bilen, Mehmet A.; Zakharia, Yousef; Milowsky, Matthew I.; Shah, Sumit A.; Bellmunt, Joaquim; Grivas, Petros; Emamekhoo, Hamid; Davis, Nancy B.; Gupta, Shilpa; Hoimes, Christopher; Campbell, Matthew T.; Alva, Ajjai; Koshkin, Vadim S.

研究方向

暂未获取到该数据
A
Amishi Y. Shah
H 指数:32论文数:290被引数:5,398
N
Nizar M. Tannir
H 指数:83论文数:1,046被引数:3.1万
O
Omar Alhalabi
H 指数:18论文数:211被引数:1,983
高建军 封面图
高建军
H 指数:56论文数:529被引数:2.1万
P
Pavlos Msaouel
H 指数:43论文数:580被引数:6,377
E
Eric Jonasch
H 指数:67论文数:624被引数:2.2万
A
Arlene O. Siefker‐Radtke
H 指数:65论文数:410被引数:1.9万
J
José A. Karam
H 指数:58论文数:610被引数:1.4万
M
Mehmet Asım Bilen
H 指数:49论文数:665被引数:1.1万
C
Christopher Hoimes
H 指数:41论文数:361被引数:7,910